A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
|Articles|January 5, 2022
CDC Committee Recommends Pfizer-BioNTech Boosters for 12-15 Year Olds
Author(s)John Parkinson
The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.
Advertisement
This afternoon, the Centers for Disease Control and Prevention’s (CDC) ACIP committee voted 13 to 1 to recommend a single Pfizer-BioNTech COVID-19 vaccine booster dose for persons aged 12-15 years at least 5 months after the primary series under the Food and Drug Administration (FDA)’s Emergency Use Authorization.
This vote comes just a couple of days after the FDA expanded its booster dose recommendations.
In addition, the FDA decreased the interim period in the second and third doses for the Pfizer-BioNTech vaccine administration, from 6 months to 5.
Yesterday, the CDC released a statement recommending that moderately or severely immunocompromised 5–11-year-olds receive an additional primary dose of vaccine 28 days after their second shot. At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for children aged 5-11.
Advertisement
Related to this article
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
4
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
5